Normo-ovulatory young women (< 37 years of age) undergoing IVF due to male factor infertility or genetic indication for pre-implantation genetic diagnosis were selected for this study. Subjects carrier of Fragile X disorder, endometriosis and polycystic ovary syndrome (PCOS) were excluded. Ovarian stimulation was carried out as previously described [32 (link)]. Briefly, short antagonist protocol was used, consisted of ovarian suppression with GnRH antagonists (0.25 mg/day, Cetrorelix, Cetrotide; Merck Serono International) and controlled ovarian hyperstimulation with human menopausal gonadotropin (HMG; Menopur) or recombinant FSH, either Gonal-F; Merck Serono or Puregon, MSD. The initial dose used was dependent upon age, body mass index, and previous IVF treatment history. When three or more follicles exceeded18 mm in diameter, 250 μg of hCG (Ovitrelle; Merck Serono) was administered to trigger ovulation. Transvaginal follicular aspiration was performed 36 h later with ultrasound guidance.
Menopur
Manufactured by Merck Group
Menopur is a laboratory equipment product manufactured by Merck Group. It is a medication used to stimulate follicle development and ovulation in women undergoing fertility treatment. Menopur contains a combination of follicle-stimulating hormone (FSH) and luteinizing hormone (LH).
Automatically generated - may contain errors
Lab products found in correlation
3 protocols using menopur
1
IVF Protocol for Male Infertility
2
IVF Protocol for Normo-ovulatory Young Women
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Normo-ovulatory young women (< 37 years of age) undergoing IVF because of male factor infertility or pre-implantation genetic diagnosis were selected for this study. Subjects a icted with BRCA mutations, Fragile X disorder, Endometriosis, or Polycystic Ovary Syndrome (PCOS) were excluded. Ovarian stimulation was carried out as previously described 54, (link)55 (link) . Brie y, a "short antagonist" protocol was used wherein controlled ovarian hyperstimulation with Human Menopausal Gonadotropins (HMG; Menopur®) or recombinant Follicle-Stimulating Hormone )rFSH, either Gonal-F®; Merck Serono or Puregon Pen®; Schering Plough) was initiated 3 days after the onset of menses. The initial gonadotropin dose used was dependent upon age, body mass index, and previous IVF treatment history. Ovarian suppression with a GnRH antagonist (0.25 mg/day, Cetrorelix, Cetrotide®; Serono International, SR) was initiated when the leading follicle was more than 12 mm in diameter. When three or more follicles exceeded18 mm in diameter, 250 µg of human Chorionic Gonadotropin (hCG; Ovitrelle®; Merck Serono) was administered to trigger ovulation. Transvaginal follicular aspiration was performed 36 hours later under ultrasound guidance.
3
IVF Protocol for Normo-ovulatory Young Women
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Normo-ovulatory young women (< 37 years of age) undergoing IVF because of male factor infertility or pre-implantation genetic diagnosis were selected for this study. Subjects a icted with BRCA mutations, Fragile X disorder, Endometriosis, or Polycystic Ovary Syndrome (PCOS) were excluded. Ovarian stimulation was carried out as previously described 54, (link)55 (link) . Brie y, a "short antagonist" protocol was used wherein controlled ovarian hyperstimulation with Human Menopausal Gonadotropins (HMG; Menopur®) or recombinant Follicle-Stimulating Hormone )rFSH, either Gonal-F®; Merck Serono or Puregon Pen®; Schering Plough) was initiated 3 days after the onset of menses. The initial gonadotropin dose used was dependent upon age, body mass index, and previous IVF treatment history. Ovarian suppression with a GnRH antagonist (0.25 mg/day, Cetrorelix, Cetrotide®; Serono International, SR) was initiated when the leading follicle was more than 12 mm in diameter. When three or more follicles exceeded18 mm in diameter, 250 µg of human Chorionic Gonadotropin (hCG; Ovitrelle®; Merck Serono) was administered to trigger ovulation. Transvaginal follicular aspiration was performed 36 hours later under ultrasound guidance.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!